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evice Availability for the
hild With Heart Disease*
ames E. Lock, MD, FACC
oston, Massachusetts
lthough pediatric heart disease is the most common
alformation in children in the first year of life, it remains
uite uncommon when viewed through the lens of human
isease as a whole. The frequency of most forms of
ongenital heart disease, 1 per 1,000 per lesion and 1
er 100 in aggregate, is dwarfed by the frequency of adult
iseases such as coronary artery disease, cancer, gastric ulcer,
nd stroke. The relative rarity of pediatric heart diseases; the
xtreme difficulty in performing randomized controlled
See page 2215
rials in children, who have issues around informed consent;
nd the relatively poor reimbursement rates for care deliv-
red to children all have conspired to prevent the develop-
ent of drugs or devices specifically designed to meet the
eeds of infants and children with heart disease. Recently, 2
evices have managed to overcome these multiple hurdles
nd obtain U.S. Food and Drug Administration approval
or pediatric cardiac indication (1,2). The presence of an
pproved device for a limited indication would make efforts
o approve any subsequent device even more difficult.
owever, the recent reports of late catastrophic erosions for
ne of the devices (3,4) highlights the importance of
ngoing work to study new and improved designs for
ediatric cardiac devices and then to obtain approval for
hose devices. For such work to succeed, the studies need to
e well designed, carefully considered, compulsively exe-
uted, and self-critical.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiology, Children’s Hospital Boston, Boston, Mas-achusetts. Dr. Lock is co-inventor for the CardioSEAL device; his affiliated hospital
eceives royalties on commercial sales and Dr. Lock receives a fraction of them.The study reported by Jones et al. (5) describing the use
f the HELEX septal occluder (HSO) to close an atrial
eptal defect (ASD) percutaneously is one such trial. The
ndications for closure of an ASD have not been established
ith precision despite a half century of surgical experience.
he consensus view that has emerged, however, seems
easonable; an ASD should be closed if there is clear
oninvasive evidence of an enlarged, volume-loaded right
entricle. The HSO has a completely different design than
ither of the 2 devices approved for pediatric intracardiac
se, the Amplatzer (AGA Medical, Golden Valley, Min-
esota) or CardioSEAL (NMT Medical, Boston, Massa-
husetts). It has what appears to be the lowest profile of the
devices, and thus may produce the smallest amount of
urbulence inside the heart. It is flexible, and thus should
ave very rare problems with late cardiac trauma. No
ntracardiac device is ideal, and the absence of an effective
elf-centering mechanism for the HELEX occluder may
esult in a higher incidence of small residual leaks in certain
atients. However, the addition of this device to the
rmamentarium of cardiologists taking care of children is a
elcome one. Perhaps more importantly, the method used
y the investigators to get through the regulatory and
ommercial hurdles of device approval can, and should,
erve as a model for others seeking to improve the care of
hildren with heart disease.
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